The role of apoptosis in CTCL has been further highlighted in a recent study that showed that concurrent inhibition of BCL2 and HDAC (Histone Deacetylase) offered synergy in the treatment of CTCL and achieved a more effective and personalized treatment for these patients [7]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.